छोड़कर सामग्री पर जाएँ

Latest News

Zydus Lifesciences down, Nuvama downgrades stock despite a strong Q1

Zydus Lifesciences down, Nuvama downgrades stock despite a strong Q1

Nuvama downgrades Zydus to ‘hold’. It says Q1 results are unlikely to be repeated, as exclusivity of epilepsy drug Trokendi is declining and revenue from blood cancer drug Revlimid remains #39;lumpy#39; Read More ​ Nuvama downgrades Zydus to ‘hold’. It says… और पढ़ें »Zydus Lifesciences down, Nuvama downgrades stock despite a strong Q1

Apple supplier Foxconn#39;s Q2 profit slips 1%, better than forecasts

Apple supplier Foxconn#39;s Q2 profit slips 1%, better than forecasts

The Taiwanese company, the world#39;s largest contract electronics maker, said net profit for the April-June quarter slipped to T$33 billion from a revised T$33.29 billion in the same period the previous year. Read More ​ The Taiwanese company, the world#39;s largest… और पढ़ें »Apple supplier Foxconn#39;s Q2 profit slips 1%, better than forecasts

Astral Q1 results: Brokerages unimpressed as stock gets #39;hold#39; and #39;reduce#39; ratings

Astral Q1 results: Brokerages unimpressed as stock gets #39;hold#39; and #39;reduce#39; ratings

Incred equities and Centrum Broking downgraded the stock to #39;hold#39; and #39;reduce#39; respectively Read More ​ Incred equities and Centrum Broking downgraded the stock to #39;hold#39; and #39;reduce#39; respectively Incred equities and Centrum Broking downgraded the stock to #39;hold#39; and #39;reduce#39;… और पढ़ें »Astral Q1 results: Brokerages unimpressed as stock gets #39;hold#39; and #39;reduce#39; ratings

hi_INहिन्दी